I-NNP
Immune-mediated diseasesCD47-guided delivery, with CD47 blockade built in.
The Next Paradigm Shift
Natural Nanoparticles (NNPs)Cell-derived. Programmable. Plug-and-play targeting and loading for your cargo.
Animated schematic: particles gather into the SHIFTBIO mark, a cell split by a turning curve; a small particle is born at its centre and comes forward as a programmable NNP. Its five surface docks light up, and each is linked to its label: targeted delivery, barrier crossing, versatile payload, repeat dosing and scalable manufacturing.
Schematic: the view moves along the inside of a blood vessel lined with cells, and particles gather into a single NNP at the closing period.
Five essentials of next-generation delivery
01
Reach target tissues beyond the liver.I-NNP
02
Cross the blood–brain barrier, cell membranes and endolysosomes.B-NNP
03
Load more cargo, and more kinds of drugs.NNP technology
04
Allow repeated doses with high purity and dramatically lower cost.NNP technology
05
Scale up with batch-to-batch consistency.NNP technology
Surface display
Internal loading
NNP technology · Step 01
Plug-and-play targeting and loading.
NSM scaffoldExplore NSM scaffold
Schematic: one NNP assembles around its cargo; a set of targeting motifs clicks onto its surface and is swapped for another set on the same scaffold.
NNP technology · Step 02
From uncertainty to predictability.
NNP Design AIExplore NNP Design AI
Schematic: candidate cargo and linker designs pour out of the NNP into a wall, are ordered by predicted cargo sorting from bright to dim; the first few light up to build first, and assay results return to the loop.
Schematic: uneven cell-derived nanoparticles pass an industrialization gate one by one and come out as consistent NNPs stacked in a grid.
Delivery platforms
01 · Targeted delivery
One NNP technology. Two delivery platforms.
CD47-guided delivery, with CD47 blockade built in.
One surface motif docks at the blood–brain barrier, the other crosses it.
Publications
Dual-mode action of scalable, high-quality engineered stem cell‑derived SIRPα-extracellular vesicles for treating acute liver failure.
Therapeutic reprogramming of circulating myeloid cells via signal regulatory protein α extracellular vesicles in acute kidney injury.
People
Bridging biology, AI, and engineering to deliver where it matters most.
Partnering
Partners bring the payload and the target biology. We bring NNP technology and delivery platforms.